Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials

INTRODUCTION: Clinical guidelines suggest a glycated hemoglobin A1c (HbA1c) target of ≤ 6.5% for type 2 diabetes patients with short duration of disease, few comorbidities and/or long life expectancy—provided this goal can be achieved safely. We explored whether initial combination treatment with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Qian, Shen, Jie, Miao, Lin, Ye, Binqi, Schepers, Cornelia, Plat, Arian, Shi, Yongquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261297/
https://www.ncbi.nlm.nih.gov/pubmed/32328953
http://dx.doi.org/10.1007/s13300-020-00819-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261297/
https://www.ncbi.nlm.nih.gov/pubmed/32328953
http://dx.doi.org/10.1007/s13300-020-00819-9

Ejemplares similares